Related Experiment Video

Updated: Jun 3, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway

Suihai Wang1, Xiang Huang, Yue Li

  • 1School of Biotechnology, Southern Medical University, Guangzhou, China.

Hepatology (Baltimore, Md.)
|March 11, 2011
PubMed
Abstract

Insights

RN181 acts as a tumor suppressor in hepatocellular carcinoma (HCC) by inhibiting ERK/MAPK signaling. Its down-regulation promotes HCC cell proliferation and tumor growth, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatology

Background:

  • Hepatocellular carcinoma (HCC) pathogenesis involves oncogene activation and tumor suppressor inactivation.
  • Chronic hepatitis virus infections are implicated in HCC development.
  • The role of RN181 in HCC tumorigenesis requires further investigation.

Purpose of the Study:

  • To investigate the role of RN181 in hepatocellular carcinoma (HCC).
  • To elucidate the molecular mechanisms by which RN181 affects HCC progression.
  • To explore RN181 as a potential therapeutic target for HCC.

Main Methods:

  • Quantitative analysis of RN181 expression in HCC cell lines and clinical samples.
  • Functional assays including cell proliferation, colony formation, and xenograft tumor growth.
  • Proteomic analysis to identify RN181-regulated proteins.
  • Western blotting and interaction network analysis to validate protein changes and signaling pathways.

Main Results:

  • RN181 was down-regulated in malignant HCC cells and tumors, correlating with pathological grade.
  • RN181 suppressed HCC cell proliferation, colony formation, and tumor growth in vivo.
  • Proteomic analysis identified 33 differentially expressed proteins regulated by RN181, many involved in MAPK signaling.
  • RN181 inhibited ERK1/2 phosphorylation, a key component of the MAPK pathway.

Conclusions:

  • RN181 functions as a tumor suppressor in HCC by inhibiting the ERK/MAPK signaling pathway.
  • RN181 down-regulation contributes to HCC tumorigenesis.
  • RN181 represents a promising therapeutic target for HCC treatment.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...